Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

Figure 2

Ex-vivo myocardial infarct size following Sitagliptin or Vildagliptin pre-treatment. (A) Ex vivo myocardial infarct size expressed as a percentage of the risk zone. A. Pre-treatment with Sitagliptin (Sita) reduced the myocardial infarct to area at risk ratio (I/R%) in isolated rat hearts perfused with buffer containing 11 but not 5 mmol/L glucose. This infarct-limiting effect was abolished in hearts Langendorff-perfused with Exendin 9–39 (Exendin), a GLP-1 receptor antagonist. *P < 0.05. N ≥ 6/group. (B) Pre-treatment with Vildagliptin (Vilda) reduced the myocardial infarct to area at risk ratio (I/R%) in isolated rat hearts perfused with buffer containing 11 but not 5 mmol/L glucose. *P < 0.05. N ≥ 6/group. (C) Ischaemic preconditioning (IPC) reduces the myocardial infarct to area at risk ratio (I/R%) in isolated rat hearts perfused with buffer containing either 5 or 11 mmol/L glucose. *P < 0.05. N ≥ 6/group.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840